NR4A1 and breast cancer: For neoadjuvant treatment of high-risk hormone receptor positive, HER2-negative BC, there are two phase III trials currently ongoing: the KEYNOTE-756 (NCT03725059), in which pembrolizumab is used in both the neoadjuvant and adjuvant phases, and CheckMate 7FL (NCT04109066), in which nivolumab is used in both settings as well.